Global regulatory frameworks and case studies of Advanced Therapy Medicinal Products (ATMPS)

Abstract Purpose Advanced Therapy Medicinal Products (ATMPs), which include tissue-engineered products, gene therapies, and somatic cell therapies, are at the pioneering of healthcare discovery and have the potential to cure ailments for which there were previously few or no therapy choices. This article compares the laws and regulations controlling the creation and approval of ATMPs in three important regions: EU, US, and Japan, and proposes a structured classification of ATMPs. Methods Regulatory frameworks established by the European Medicines Agency (EMA), the Food and Drug Administration (FDA) of the United States, and the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan were reviewed. Special focus was placed on accelerated mechanisms like the FDA's RMAT designation, the EU's PRIME program, and Japan's Sakigake and conditional approval systems. Results The article examines several noteworthy ATMP case studies to demonstrate real-world uses and difficulties within these frameworks: Beqvez, a haemophilia A gene treatment authorized in the EU under accelerated approval; MACI, a tissue-engineered autologous chondrocyte implant approved in the US; Collategene, the first DNA plasmid gene therapy approved in Japan; and Alofisel, a stem cell therapy. Throughout the lifecycle of ATMPs, these instances highlight the intricate interactions among scientific discovery, regulatory rigor, and commercial sustainability. Conclusion The significance of internationally standardized regulatory strategies and flexible approval models that guarantee prompt patient access while upholding strict safety, effectiveness, and quality requirements across the product lifecycle is emphasized in the article's conclusion .